What is HC Wainwright’s Forecast for PTGX Q3 Earnings?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Protagonist Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $2.55 for the quarter, down from their prior estimate of $2.88. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $3.69 per share.

A number of other research analysts have also issued reports on PTGX. Truist Financial lifted their target price on Protagonist Therapeutics from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Barclays upped their price target on shares of Protagonist Therapeutics from $151.00 to $153.00 and gave the company an “overweight” rating in a report on Thursday. Wall Street Zen upgraded shares of Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Johnson Rice set a $165.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, July 17th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Protagonist Therapeutics in a report on Friday, May 15th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and an average target price of $126.71.

Protagonist Therapeutics Stock Up 6.5%

Shares of Protagonist Therapeutics stock opened at $146.18 on Friday. The firm has a market cap of $9.40 billion, a price-to-earnings ratio of 141.92 and a beta of 1.78. The business has a fifty day simple moving average of $123.38 and a 200-day simple moving average of $104.93. Protagonist Therapeutics has a fifty-two week low of $50.49 and a fifty-two week high of $148.00.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a return on equity of 12.98% and a net margin of 29.40%.The company had revenue of $213.47 million for the quarter, compared to analysts’ expectations of $210.91 million. The firm’s revenue for the quarter was up 3746.8% on a year-over-year basis.

Institutional Trading of Protagonist Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its holdings in shares of Protagonist Therapeutics by 30.6% during the first quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock valued at $482,000 after acquiring an additional 2,334 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after purchasing an additional 348 shares during the period. Millennium Management LLC lifted its holdings in shares of Protagonist Therapeutics by 283.6% in the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock valued at $6,493,000 after purchasing an additional 99,269 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Protagonist Therapeutics in the second quarter worth $987,000. Finally, Guggenheim Capital LLC grew its holdings in shares of Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after buying an additional 303 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. The trade was a 53.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the sale, the chief executive officer directly owned 523,478 shares in the company, valued at $52,410,617.36. This trade represents a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 102,000 shares of company stock worth $10,436,340 over the last 90 days. Insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.